enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Sangamo Therapeutics Stock Plunges As Pfizer Terminates ...

    www.aol.com/sangamo-therapeutics-stock-plunges...

    On Monday, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for ...

  3. List of largest biomedical companies by market capitalization

    en.wikipedia.org/wiki/List_of_largest_biomedical...

    The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.

  4. Got $5,000? 2 Top Healthcare Stocks to Buy in 2025 and Hold ...

    www.aol.com/got-5-000-2-top-161500333.html

    The company's third-quarter revenue grew by 20% year over year to $11.4 billion, a terrific performance for almost any other pharmaceutical company. Got $5,000? 2 Top Healthcare Stocks to Buy in ...

  5. Adverum Biotechnologies - Wikipedia

    en.wikipedia.org/wiki/Adverum_Biotechnologies

    Adverum Biotechnologies, Inc., formerly known as Avalanche Biotechnologies, [2] is a publicly traded [3] clinical stage gene therapy company located in Redwood City, California. [4] The company is targeting unmet medical needs for serious ocular and rare diseases, including wet age-related macular degeneration (wet AMD).

  6. Why Did BMO Capital Markets Raise Price Target For Gene Stock ...

    www.aol.com/news/why-did-bmo-capital-markets...

    BMO Capital Markets has raised the price target on Beam Therapeutics Inc (NASDAQ: BEAM) to $61 from $41, with a Market Perform rating unchanged. The model changes include updated collaboration ...

  7. Oxford Biomedica - Wikipedia

    en.wikipedia.org/wiki/Oxford_BioMedica

    The company was established in 1995 as a spin out from the University of Oxford. [3] It was the subject of an initial public offering on the Alternative Investment Market in 1996. [4] In 2018, OXBs gene therapy for Parkinson's disease became the subject of a commercialization deal with Axovant Sciences. [5]

  8. bluebird bio - Wikipedia

    en.wikipedia.org/wiki/Bluebird_bio

    bluebird bio, Inc., based in Somerville, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders. [1]The company's only - in the European Union (EU) - approved drug is betibeglogene autotemcel (Zynteglo), which treats transfusion-dependent beta thalassemia (TDT), a rare genetic blood disorder, and has been approved for use by the European Medicines ...

  9. 10 Most Promising Gene Therapy Companies to Watch - AOL

    www.aol.com/news/10-most-promising-gene-therapy...

    For more companies, take a look at 5 Most Promising Gene Therapy Companies to Watch. Gene therapy is a revolutionary new technology that has followed the growing advances in computing power. The ...